7-OH vs Natural Kratom Leaf: The Line Regulators Drew in 2026

If you buy kratom in 2026, one distinction now matters more than strain color, format, or brand: the difference between natural kratom leaf and concentrated or synthetic 7-hydroxymitragynine (7-OH) products. Federal regulators, state legislatures, and health departments have spent the past year drawing a hard legal line between the two — and on July 1, 2026, the DEA formally moved to place concentrated 7-OH on the wrong side of it.

This guide explains what 7-OH actually is, why regulators treat enhanced 7-OH products differently from traditional leaf, exactly what the DEA's 2026 scheduling action does and does not cover, and how responsible buyers and vendors are navigating the new landscape. Nothing here is legal or medical advice — it is a plain-language map of a fast-moving regulatory situation, current as of mid-July 2026.

What Is 7-Hydroxymitragynine?

The kratom tree (Mitragyna speciosa) produces dozens of alkaloids in its leaves. The two most studied are mitragynine — by far the most abundant — and 7-hydroxymitragynine, usually shortened to 7-OH. In natural, unaltered leaf, 7-OH is present only in trace amounts, typically a small fraction of the mitragynine content. That trace presence is part of the plant's natural chemistry and has been consumed in traditional leaf preparations for generations in Southeast Asia.

What changed the regulatory picture was not the leaf. It was a wave of manufactured products — tablets, gummies, shots, and extracts — containing 7-OH at concentrations far beyond anything found in nature. Some are produced by chemically converting mitragynine into 7-OH; others isolate and concentrate it. Regulators, including the FDA, describe these enhanced products as functionally different from botanical kratom: HHS Secretary Robert F. Kennedy, Jr. characterized 7-OH and related substances as dangerous opioids in the government's July 2026 announcements, and the FDA has issued warning letters to companies selling concentrated 7-OH since mid-2025.

What the DEA Actually Did on July 1, 2026

On July 1, 2026, the Drug Enforcement Administration filed two Notices of Intent to temporarily place substances into Schedule I of the Controlled Substances Act. Understanding the mechanics matters, because headlines compressed a nuanced action into "kratom banned" — which is not what happened.

• Notice one covers 7-hydroxymitragynine above a specified threshold. The threshold, as published in the Federal Register on July 6, 2026 (FR Doc 2026-13580), covers botanical material of Mitragyna speciosa containing more than 0.050 percent 7-OH on a dry-weight basis, along with non-botanical product limits described in the notices. Material at or below the natural trace threshold is not covered.
• Notice two (FR Doc 2026-13581) covers three 7-OH-related substances: mitragynine pseudoindoxyl (MP), dihydro-7-hydroxymitragynine (MGM-15), and 9-fluoro-7-hydroxymitragynine (MGM-16) — synthetic or chemically modified compounds sold in some "enhanced" products.
• Before the DEA acted, the Department of Health and Human Services confirmed that synthetic 7-OH and the three related substances have no currently accepted medical use and a high potential for abuse — the statutory test for Schedule I.
• These are notices of intent, not final orders. The notices were published in the Federal Register on July 6, 2026, and temporary scheduling orders are expected to take effect roughly 30 days after publication — early August 2026 — unless the process changes.

Alongside the DEA notices, HHS opened a public Request for Information (docket HHS-OASH-2026-0232) seeking comment on the proposed 7-OH threshold. That comment window closes July 31, 2026. If you are a consumer, vendor, or researcher with a stake in where the threshold lands, the docket at regulations.gov is the formal channel to be heard — over a thousand comments had already been filed within the first week.

What the Federal Action Does NOT Do

Three things the July 2026 action explicitly does not do, and where confusion is most common:

• It does not schedule natural kratom leaf. Mitragynine and ordinary botanical kratom containing only naturally occurring trace 7-OH below the threshold remain federally unscheduled. The DEA's own notices distinguish traditional botanical kratom from enhanced products.
• It does not override state law in either direction. States that fully ban kratom still ban it. States that regulate it under Kratom Consumer Protection Acts still regulate it. The federal threshold adds a layer on top of the state patchwork; it does not replace it.
• It is not yet in force. Until the temporary scheduling orders are issued and take effect, the notices signal intent. Vendors and retailers, however, began pulling high-7-OH products well before the effective date, because handling Schedule I substances after the order lands carries the full weight of federal criminal law.

It is also worth remembering the history: the DEA announced an intent to schedule mitragynine and 7-OH broadly in 2016 and withdrew it after massive public and congressional pushback. The 2026 action is narrower by design — it targets the concentrated-product category regulators consider most dangerous while leaving the botanical leaf question open. That precision is exactly why the natural-vs-7-OH distinction now defines the market.

How the 7-OH Product Wave Triggered the Crackdown

To understand why regulators moved in 2026, look at what happened on shelves between 2023 and 2025. Concentrated 7-OH tablets, chewables, and shots — often brightly packaged and sold at gas stations and smoke shops alongside energy products — went from a niche curiosity to one of the fastest-growing segments of the botanical retail market. Unlike traditional leaf powder, these products delivered 7-OH in isolated, milligram-dosed form, frequently without any indication that the compound was chemically converted or concentrated rather than naturally occurring.

Federal safety data tracked the rise. According to the DEA's own Federal Register notice, the FDA's adverse event reporting system (FAERS) logged a single 7-hydroxymitragynine case in 2023 and two in 2024 — then 66 in 2025, with 17 more in the first weeks of 2026. Of the 86 total cases in the database at the time of the DEA's February 2026 query, 79 were classified as serious, and nine involved death. Poison control centers reported 1,690 kratom-related exposure calls between January and July 2025 alone, a significant jump over the prior year. The FDA issued its first warning letter to a company selling concentrated 7-OH in June 2025 and formally recommended scheduling later that year.

The industry's own trade response is telling: the American Kratom Association — the sector's largest advocacy group — supported action against synthetic 7-OH while defending natural leaf, and compliant vendors had already refused to carry the concentrated products. When the manufacturer side of an industry and its regulators agree that a product category is the problem, that category's days are numbered. The July 2026 notices are the formal end of that arc.

Natural Leaf and Leaf Extracts: What Stays on the Legal Side

Because the scheduling threshold is defined by 7-OH concentration rather than by product format, the legal side of the line includes more than raw powder. Traditional formats that remain outside the federal action, provided their 7-OH content sits at natural trace levels below the 0.050 percent dry-weight threshold:

• Whole-leaf powder and crushed leaf — milled dried leaf with its natural alkaloid profile intact. This is the baseline product the entire traditional market is built on.
• Leaf capsules — the same powder in pre-measured capsule form; nothing about encapsulation changes the alkaloid chemistry.
• Mitragynine-standardized extracts — concentrates built around mitragynine, the plant's primary alkaloid, rather than converted 7-OH. MIT45, whose name references its 45 percent mitragynine extract standard, built the best-known line in this category using a triple-purification process, and publishes certificates of analysis by lot number.
• Teas and traditional preparations — brewed leaf remains what it has always been.

The category that does not survive: anything marketed on its 7-OH content — "7-OH tablets," "7-hydroxy shots," enhanced gummies disclosing 7-OH milligrams per piece — plus products built on the three named synthetic derivatives. If a label brags about 7-OH, it is describing the exact property the DEA is scheduling.

How to Read a COA for 7-OH in 2026

Certificates of analysis used to be a trust signal. As of this year they are a compliance document. Here is what to check, in order:

• Batch match. The COA's lot number must match the package in your hand. A generic, undated lab sheet proves nothing about your batch.
• Alkaloid panel. Look for mitragynine and 7-hydroxymitragynine listed separately, with percentages. Natural leaf typically shows mitragynine in the low single digits and 7-OH at a small fraction of that — comfortably below the 0.050 percent federal threshold.
• Accredited lab. The certificate should name an independent, ISO-accredited laboratory, not the vendor's own bench.
• Contaminant screens. Heavy metals (lead, cadmium, arsenic, mercury) and microbials (salmonella, E. coli, mold, yeast) round out the safety picture — the same panels AKA GMP audits expect.

A vendor that cannot produce this document for the specific batch you are buying has, in 2026, failed the most basic test the market now imposes. Every vendor featured on this site is screened on exactly this standard, and our guide to buying kratom online legally walks through the full vetting process.

How States Drew the Same Line First

The federal threshold did not appear out of nowhere. Through late 2025 and the first half of 2026, states converged on the same distinction from several directions:

Notice the pattern. States that chose regulation (Rhode Island, the 30-plus KCPA states) and states that chose prohibition (Tennessee, Kansas, Connecticut) both singled out concentrated 7-OH. Even Ohio — which stopped short of banning natural leaf — moved against synthetic 7-OH within days of the governor's request. Whatever a state's overall posture, elevated 7-OH is the category regulators agree on. We cover each state's 2026 changes in detail in our 2026 kratom regulation landscape guide.

Why Responsible Vendors Sit on the Natural-Leaf Side

The vendors we feature at KratomDeals were selected around lab-tested natural leaf and standardized leaf extracts long before the DEA acted, and the 2026 action validates that screen. Here is what the natural-leaf side of the line looks like in practice:

• Third-party Certificates of Analysis (COAs) that disclose alkaloid content — including 7-OH levels — plus heavy-metal and microbial screens. A vendor that publishes batch-level alkaloid data gives you the exact number the new federal threshold cares about.
• AKA GMP participation. The American Kratom Association's Good Manufacturing Practices program audits facilities and processes. The AKA has also long opposed synthetic and adulterated 7-OH products — its model KCPA legislation bans synthetic alkaloid additives outright.
• No "enhanced 7-OH" product lines. Leaf powders, leaf capsules, and mitragynine-standardized extracts (like MIT45's triple-purified extract line, built around mitragynine rather than 7-OH conversion) sit on the traditional side of the distinction.
• Geo-blocking. Compliant vendors refuse orders to ban states — Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Tennessee, Vermont, Wisconsin, and Washington, D.C. — and update their no-ship lists as laws change.

What Buyers Should Do Now

Practical takeaways for anyone purchasing kratom in the second half of 2026:

• Check the COA for 7-OH content. The federal threshold for botanical material is 0.050 percent 7-OH on a dry-weight basis. Natural leaf tests comfortably below it; if a product's paperwork shows elevated 7-OH — or no alkaloid data at all — treat that as disqualifying.
• Avoid products marketed on 7-OH potency. Tablets and shots advertising 7-OH content by the milligram are precisely what the DEA notices target and what Ohio, Florida, Mississippi, and Colorado have already restricted.
• Know your state. A federally compliant natural-leaf product is still illegal in the nine full-ban states. Our state coverage — including Tennessee, Kansas, and California — breaks down each jurisdiction.
• Watch the effective date. The temporary scheduling orders are expected in early August 2026. Product mixes at retail may shift quickly around that date.

One more piece of perspective. In 2016, the DEA tried to schedule mitragynine and 7-OH wholesale and was forced into an unprecedented withdrawal by public comment volume and congressional letters. The lesson regulators took from that episode is visible in the 2026 design: target the concentrated products that generate the adverse-event data, spare the traditional leaf that generates the political backlash, and put a measurable chemical threshold between the two so enforcement does not depend on marketing language. Whether that compromise holds — or becomes the first step toward broader scheduling, as some senators are urging — will be decided over the coming year in the comment dockets, the courts, and the statehouses.

The line regulators drew in 2026 is, in the end, the same line careful buyers have always used: know exactly what is in the product, from a vendor that proves it. The difference now is that the wrong side of that line is about to be Schedule I.